Analysis: Pharma's Path Ahead For COVID-19 R&D

By Andrew Odame-Kwakye

The therapeutic solutions and vaccines developed by the biopharma industry during the pandemic have allowed society to start imagining life after COVID-19. However, more tools and treatments are needed to control the virus. COVID-19 has become a leading cause of death worldwide, and continues to profoundly affect patients, families and societies and strain health care systems.

Three pressing issues stand out and require the collaborative efforts of the biopharma industry to slow the pandemic, reduce deaths and hospitalizations, and return life to something resembles normality: understanding long COVID, growing the arsenal of anti-infectives and tackling virus variants.